Document text
Principal Investigator: Rajagopal Ramesh
Organization: UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
Fiscal Year: 2023
Award: $343,921
Funding agency: National Cancer Institute
Effective control of lung cancer continues to remain a clinical challenge resulting in poor five-year survival
rate. Currently available therapies while showing promise have had limitations. Therefore, continued efforts for
developing new therapeutic agents and systemic treatment modalities are warranted for treating lung cancer.
This application addresses focuses on testing an improved interleukin (IL)-24 gene-based non-viral therapeutic
for cancer.
The PI’s laboratory has identified by modifying a phosphorylation (p) site in the wild-type IL-24 tumor
suppressor/cytokine gene, the antitumor activity is improved and enhanced. Preliminary studies demonstrated
replacement of a specific phosphorylation site in the wild-type IL-24 cDNA produced IL-24 protein (herein
referred to as IL-24mt) that exhibited increased intracellular protein stability, secretion, and enhanced antitumor
activity against lung cancer cells when compared to wild-type IL-24 (IL-24wt). Furthermore, inhibition of Gli1,
and PD-L1 by IL-24wt both of which are known to support tumor growth, drug resistance, and metastasis was
observed. Combinatorial approach with Gli1 inhibitor produced greater inhibitory activity on tumor cell growth,
migration and invasion compared to individual treatments in vitro. Next, for applying IL-24-based therapeutic in
vivo we adopted a non-viral delivery approach and used a cationic lipid-based nanoparticle (NP) system. The
NP was decorated with a tumor-targeted ligand such as transferrin (Tf) for selective delivery of IL-24mt to tumor
depots. Bio-distribution studies demonstrated TfNP preferentially accumulated in subcutaneous tumor and lung
metastasis. Further, systemic administration of IL-24 contained in TfNP (IL-24-TfNP) in mice demonstrated a
marked delay in lung tumor growth. To our knowledge, apart from our own observation reported herein, there
are no prior reports demonstrating IL-24mt exhibited improved and enhanced anticancer activity over IL-24wt
and it’s testing as a cancer therapeutic for lung cancer.
On the basis of our new findings, we hypothesize that IL-24mt will demonstrate superior anticancer efficacy
over IL-24wt both in vitro and in vivo that will be further enhanced when combined with inhibitors against Gli1,
or PD-L1. To test our hypothesis we have identified three specific aims: Aim 1. Conduct biologic and molecular
studies of IL-24mt and demonstrate its superior antitumor activity over IL-24wt in vitro. Aim 2. Deliver IL-24mt
contained in TfNP and demonstrate the improved therapeutic efficacy in murine and human tumor xenograft
tumor models. Aim 3. Conduct IL-24mt combinatorial studies with inhibitors against Gli1, and PDL1 in in vitro
and in vivo tumor models.
Demonstrating improved efficacy for IL-24mt over IL-24wt will lead to advanced studies aiding in clinical
translation. Our findings will also have application against broad-spectrum of human cancers.
Terms: <Abscission><Ad vector><Address><Adenoviral Vector><Adenoviridae><Adenovirus Vector><Adenoviruses><Adopted><Angiogenesis Antagonists><Angiogenesis Blockers><Angiogenesis Inhibitors><Angiogenetic Antagonists><Angiogenetic Inhibitors><Angiogenic Antagonists><Angiogenic Inhibitors><Angiostatic Agents><Anti-Angiogenetic Agents><Anti-Angiogenic Agents><Anti-Angiogenic Drugs><Anti-Cancer Agents><Antiangiogenesis Agents><Antiangiogenic Agents><Antiangiogenic Drugs><Antineoplastic Agents><Antineoplastic Drugs><Antineoplastics><Apoptotic><B7-H1><B7H1><Biodistribution><Biological><CD274><CD71><CXC-R4><CXCR-4><CXCR4><CXCR4 gene><Cancer Biology><Cancer Drug><Cancer Patient><Cancer Treatment><Cancers><Cell Communication and Signaling><Cell Signaling><Cell Survival><Cell Viability><Cellular Expansion><Cellular Growth><Chemokine Receptor Gene><Clinic><Clinical><Clinical Evaluation><Clinical Testing><Complementary DNA><Cytokine Gene><D2S201E><Diagnosis><Drug resistance><Excision><Exhibits><Extirpation><FB22><Gene Delivery><Genes><Goals><HM89><HSY3RR><Human><IL-24 protein><IL10B><IL24><IL24 gene><In Vitro><Individual><Innovative Therapy><Interleukin-24><Interleukins><Intracellular Communication and Signaling><Invaded><Investigators><LAP3><LCR1><LESTR><Laboratories><Ligands><Lung Neoplasms><Lung Tumor><MDA7><MDA7 Protein><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Lung><Malignant neoplasm of lung><Mediating><Melanoma Differentiation Associated Protein 7><Metastasis><Metastasis to the Lung><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Neoplasm to the Lung><Metastatic Tumor><Metastatic Tumor to the Lung><Mice><Mice Mammals><Mob-5><Modality><Modeling><Modern Man><Molecular><Murine><Mus><NPY3R><NPYR><NPYRL><NPYY3R><Neoplasm Metastasis><Neoplastic Disease Chemotherapeutic Agents><Neovascularization Inhibitors><Non-Polyadenylated RNA><Normal Tissue><Normal tissue morphology><PD-L1><PDL-1><PDL1><Pathology><Patients><Phosphorylation><Phosphorylation Site><Process><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Property><Protein Phosphorylation><Proteins><Pulmonary Cancer><Pulmonary Neoplasms><Pulmonary malignant Neoplasm><RNA><RNA Gene Products><Removal><Reporting><Research Personnel><Researchers><Ribonucleic Acid><ST16><ST16 Protein><Secondary Neoplasm><Secondary Tumor><Siderophilin><Signal Transduction><Signal Transduction Systems><Signaling><Site><Suppression of Tumorigenicity 16 Protein><Surgical Removal><Survival Rate><System><TFR gene><TFR protein><TFR1><TFRC><TFRC gene><TRFR><Testing><Therapeutic><Therapeutic Agents><Time><Toxic effect><Toxicities><Transferrin><Transferrin Receptor><Transferrin Receptor 1><Treatment Efficacy><Tumor Cell><Tumor Suppressor Proteins><Tumor-Specific Treatment Agents><adeno vector><adenovector><antagonism><antagonist><anti-cancer><anti-cancer activity><anti-cancer drug><anti-cancer therapy><antiangiogenic><anticancer><anticancer activity><anticancer agent><anticancer drug><anticancer therapy><biologic><biological signal transduction><cDNA><cancer metastasis><cancer therapy><cancer-directed therapy><cell growth><chemokine receptor><clinical relevance><clinical test><clinical translation><clinically relevant><clinically translatable><combinatorial><delivery vector><delivery vehicle><drug resistant><effective therapy><effective treatment><gene therapeutics><gene-based therapeutic><gene-based therapeutics><genes therapeutic><genes therapeutics><improved><in vivo><inhibitor><innovate><innovation><innovative><interest><intervention efficacy><lipid based nanoparticle><lipid nanoparticle><lung cancer><lung cancer cell><lung metastasis><malignancy><mda-7 gene product><mda-7 protein><metastasize to the lung><migration><multidisciplinary><nano particle><nano-sized particle><nanoparticle><nanosized particle><neoplasm/cancer><neoplastic cell><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><pre-clinical study><preclinical study><programmed cell death ligand 1><programmed cell death protein ligand 1><protein death-ligand 1><pulmonary metastasis><research clinical testing><resection><resistance to Drug><resistant to Drug><statistics><subcutaneous><subdermal><therapeutic efficacy><therapeutic gene><therapy efficacy><tumor><tumor cell metastasis><tumor growth><tumor suppressor><tumor xenograft>